LabCorp
LabCorp is a leading provider of laboratory testing services, focused on delivering accurate and clinically relevant tests to healthcare providers. The company develops innovative diagnostic tests that enhance the quality of patient care and support clinical decision-making. Its diverse customer base includes physicians, hospitals, managed care organizations, private employers, military and law enforcement agencies, as well as pharmaceutical and biotechnology firms. LabCorp aims to improve health outcomes by offering a wide range of laboratory services that facilitate disease diagnosis, monitoring, and treatment. Through its commitment to innovation and precision in testing, LabCorp plays a vital role in the healthcare ecosystem, aiding physicians and patients alike in managing health effectively.
Geneoscopy
Series C in 2025
Geneoscopy, LLC, based in Saint Louis, Missouri, specializes in developing non-invasive diagnostic tests aimed at preventing, detecting, and guiding treatment for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, the company utilizes a proprietary platform that extracts stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the effects of DNA mutations associated with the disease. Geneoscopy's technology not only enhances screening compliance but also facilitates the early detection of colorectal neoplasms, ultimately aiming to reduce morbidity and mortality linked to colorectal cancer. The company is also exploring additional applications of its technology for related gastrointestinal conditions.
Geneoscopy
Series B in 2021
Geneoscopy, LLC, based in Saint Louis, Missouri, specializes in developing non-invasive diagnostic tests aimed at preventing, detecting, and guiding treatment for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, the company utilizes a proprietary platform that extracts stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the effects of DNA mutations associated with the disease. Geneoscopy's technology not only enhances screening compliance but also facilitates the early detection of colorectal neoplasms, ultimately aiming to reduce morbidity and mortality linked to colorectal cancer. The company is also exploring additional applications of its technology for related gastrointestinal conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.